Gallium Scan in the Evaluation of Post Chemotherapy Mediastinal Residual Masses of Aggressive Non-Hodgkin's Lymphoma

References

• Canellos G. P. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931–933, editorial
   PubMed Web of Science ®Google Scholar
• Haioun C., Lepage E., Gisselbrecht C., et al. High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. Ann Oncol 1998; 9(Suppl. 1)S5–S8
   PubMedGoogle Scholar
• Popat U., Przepiork D., Champlin R., et al. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: Mediastinal localization predicts for a favorable outcome. J Clin Oncol 1998; 16: 63–69
   PubMed Web of Science ®Google Scholar
• Sehn L. H., Antin J. H., Shulman L. N., et al. Primary diffuse large B-cell lymphoma of the mediastinum: Outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998; 91: 717–723
   PubMed Web of Science ®Google Scholar
• Kaplan W. D., Jochelson M. S., Herman T. S., et al. Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8: 1966–1970
   PubMed Web of Science ®Google Scholar
• Tumeh S. S., Rosenthal D. S., Kaplan W. D., et al. Lymphoma: evaluation with 67Ga SPECT. Radiology 1987; 164: 111–114
   PubMed Web of Science ®Google Scholar
• Drossman S. R., Schiff R. G., Kronfeld G. D., et al. Lymphoma of the mediastinum and neck: Evaluation with Ga-67 imaging and CT correlation. Radiology 1990; 174: 171–175
   PubMed Web of Science ®Google Scholar
• Front D., Israel O., Epelbaum R., et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990; 175: 515–519
   PubMed Web of Science ®Google Scholar
• Draisma A., Maffioli L., Gasparini M., et al. Gallium-67 as a tumor-seeking agent in lymphomas — A review. Tumori 1998; 84: 434–441
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Carde P., Meerwaldt J. H., van Glabbeke M., et al. Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma: The 1980–1985 EORTC trial. Ann Oncol 1991; 2: 431–435
   PubMed Web of Science ®Google Scholar
• Naccache P., Munck J. N., Brault P., et al. Long term follow-up of a super CHVmP-VB regimen in patients with high risk non-Hodgkin's lymphoma of aggressive histology. Blood 1996; 88(S1)452a, abstr 1796
   Google Scholar
• Coiffier B. Fourteen years of high-dose CHOP (ACVB regimen): Preliminary conclusions about the treatment of aggressive-lymphoma patients. Ann Oncol 1995; 6: 211–217
   PubMed Web of Science ®Google Scholar
• Morel P., Munck J. N., Coiffier B., et al. ECVB: A new high dose CHOP regimen followed by an intensive consolidation in patients aged <60 years with agressive lymphoma presenting with only one adverse prognostic factor of the international prognostic index. An interim analysis of the LNH 93–2 protocol on 433 patients. Blood 1997; 90(S1)587a, abstr 2610
   Google Scholar
• Abrahamsen A. F., Lien H. H., Aas M., et al. Magnetic resonance imaging and 67-Gallium scan in mediastinal malignant lymphoma: A prospective pilot study. Ann Oncol 1994; 5: 433–436
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Zompatori M., Bendandi M., et al. Monitoring bulky mediastinal disease with Gallium-67, CT-Scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1996; 22: 131–135
   PubMed Web of Science ®Google Scholar
• Front D., Ben-Haim S., Israel O., et al. Lymphoma: Predictive value of Ga-67 scintigraphy after treatment. Radiology 1992; 182: 359–363
   PubMed Web of Science ®Google Scholar
• Hill M., Cunningham D., MacVicar D., et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993; 11: 2273–2278
   PubMed Web of Science ®Google Scholar
• Ziegels P., Nocaudie M., Huglo D., et al. Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 scanning in the assessment of lymphomas. Eur J Nucl Med 1995; 22: 126–131
   PubMedGoogle Scholar
• Kim D., Mauch P., Shaffer K., et al. Large-cell and immunoblastic lymphoma of the mediastinum: Prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993; 11: 1336–1343
   PubMed Web of Science ®Google Scholar
• Gasparini M. D., Balzarini L., Castellani M. R., et al. Current role of Gallium scan and magnetic resonance in the management of mediastinal Hodgkin lymphoma. Cancer 1993; 72: 577–582
   PubMed Web of Science ®Google Scholar
• Rahmouni A., Tempany C., Jones R., et al. Lymphoma: Monitoring tumor size and signal intensity with MR imaging. Radiology 1993; 188: 445–451
   PubMed Web of Science ®Google Scholar
• Jerusalem G., Beguin Y., Fassotte M. F., et al. Whole-body FDG-PET post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical CT scan imaging. Blood 1997; 90(S1)1997, abstr 1498
   Google Scholar
• Newman J. S., Francis I. R., Kaminski M. S., et al. Imaging of lymphoma with PET with 2-(F-l 8)-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 190: 111–116
   PubMed Web of Science ®Google Scholar
• Hoh C. K., Glaspy J., Rosen P., et al. Whole-body FDG PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343–348
   PubMed Web of Science ®Google Scholar
• Janicek M., Kaplan W., Neuberg D., et al. Early restaging Gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15: 1631–1637
   PubMed Web of Science ®Google Scholar